PMID- 25676401
OWN - NLM
STAT- MEDLINE
DCOM- 20151105
LR  - 20190221
IS  - 1999-6187 (Electronic)
IS  - 1009-3419 (Print)
IS  - 1009-3419 (Linking)
VI  - 18
IP  - 2
DP  - 2015 Feb
TI  - [Crizotinib treatment in a lung adenocarcinoma harboring ALK fusion gene with 
      bone marrow metastasis: case report and literature review].
PG  - 85-8
LID - 10.3779/j.issn.1009-3419.2015.02.06 [doi]
AB  - BACKGROUND AND OBJECTIVE: Distant metastasis was common in lung cancer, 
      especially patients with bone marrow metastasis had poor prognosis and there were 
      few effective methods. Crizotinib had been confirmed to be used in anaplastic 
      lymphoma kinase (ALK) positive lung adenocarcinoma, but the efficacy in lung 
      cancer with bone marrow metastasis was unknown. In the present study, we reported 
      one case of ALK-positive lung adenocarcinoma with bone marrow matastasis given 
      crizotinib treatment, the safety and efficacy was summarized. METHODS: ALK fusion 
      was tested by fluorescence in situ hybridization (FISH). Crizotinib was given 
      with dose of 250 mg, bid. Objective response was evaluated by Response Evaluation 
      Criteriation in Solid Tumours (RECIST) v1.1 and bone marrow response was 
      evaluated by bone marrow puncture and biopsy. Adeverse events were evaluated 
      according to Common Terminology Criteria for Adverse Events (CTC AE) v4.0. 
      RESULTS: The patient achieved partial response (PR) after 6 weeks of crizotinib, 
      especially the objective response of bone marrow metastasis was complete response 
      (CR). The patient stopped crizotinib because of pneumonia. The progression free 
      survival (PFS) and overall survival (OS) was 20 weeks and 22 weeks respectively. 
      CONCLUSION: Crizotinib could be an effective method for ALKpositive lung cancer 
      with bone marrow metastasis and showed good tolerance.
FAU - Li, Xiaoyan
AU  - Li X
AD  - Department of Lung Cancer, 307 Hospital of PLA, Affiliated to Academy of Military 
      Medical Sciences, Beijing 100071, China.
FAU - Liu, Xiaoqing
AU  - Liu X
AD  - Department of Lung Cancer, 307 Hospital of PLA, Affiliated to Academy of Military 
      Medical Sciences, Beijing 100071, China.
FAU - Gao, Fang
AU  - Gao F
AD  - Department of Lung Cancer, 307 Hospital of PLA, Affiliated to Academy of Military 
      Medical Sciences, Beijing 100071, China.
FAU - Yin, Xiaodan
AU  - Yin X
AD  - Department of Lung Cancer, 307 Hospital of PLA, Affiliated to Academy of Military 
      Medical Sciences, Beijing 100071, China.
LA  - chi
PT  - Case Reports
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - China
TA  - Zhongguo Fei Ai Za Zhi
JT  - Zhongguo fei ai za zhi = Chinese journal of lung cancer
JID - 101126433
RN  - 0 (Pyrazoles)
RN  - 0 (Pyridines)
RN  - 53AH36668S (Crizotinib)
RN  - EC 2.7.10.1 (ALK protein, human)
RN  - EC 2.7.10.1 (Anaplastic Lymphoma Kinase)
RN  - EC 2.7.10.1 (Receptor Protein-Tyrosine Kinases)
SB  - IM
MH  - Adenocarcinoma/*drug therapy/enzymology/genetics/pathology
MH  - Adenocarcinoma of Lung
MH  - Adult
MH  - Anaplastic Lymphoma Kinase
MH  - Bone Marrow Neoplasms/*secondary
MH  - Crizotinib
MH  - Female
MH  - Gene Fusion
MH  - Humans
MH  - Lung Neoplasms/*drug therapy/enzymology/genetics/pathology
MH  - Pyrazoles/*administration & dosage/adverse effects
MH  - Pyridines/*administration & dosage/adverse effects
MH  - Receptor Protein-Tyrosine Kinases/*genetics/metabolism
MH  - Treatment Outcome
PMC - PMC5999841
EDAT- 2015/02/14 06:00
MHDA- 2015/11/06 06:00
PMCR- 2015/02/20
CRDT- 2015/02/14 06:00
PHST- 2015/02/14 06:00 [entrez]
PHST- 2015/02/14 06:00 [pubmed]
PHST- 2015/11/06 06:00 [medline]
PHST- 2015/02/20 00:00 [pmc-release]
AID - zgfazz-18-2-85 [pii]
AID - 10.3779/j.issn.1009-3419.2015.02.06 [doi]
PST - ppublish
SO  - Zhongguo Fei Ai Za Zhi. 2015 Feb;18(2):85-8. doi: 
      10.3779/j.issn.1009-3419.2015.02.06.